Aims: To investigate the usefulness of contrast-enhanced ultrasonography for diagnosing renal cell carcinoma (RCC) in dialysis patients.
Introduction
Dialysis patients are at a higher risk of developing renal cell carcinoma (RCC) compared with healthy individuals. [1] Specifically, the reported prevalence of RCC in hemodialysis patients with acquired cystic disease of the kidney (ACDK) is 3% to 7%. [1] It has been reported that the prevalence of ACDK increases with the duration of hemodialysis, and that 90% of patients with a hemodialysis duration of ≥5 years have ACDK. [1, 2] Recently, although a tendency towards improved survival of patients after initiation of hemodialysis has been observed [3, 4] , and mortality due to cardiovascular disease in hemodialysis patients is decreasing, mortality due to malignant tumors in these patients has not decreased [3] ; thus, early detection of RCC by imaging is important in hemodialysis patients.
At present, ultrasonography and computed tomography (CT) are routinely used to diagnose renal masses in dialysis patients. In particular, evaluation of the presence or absence of blood flow is useful to differentiate between benign and malignant masses, and therefore, dynamic contrast-enhanced CT is considered a useful modality in patients who can undergo this examination. However, the contrast enhancement of RCCs associated with ACDK is often lower than that of conventional RCC, [5] which sometimes makes it difficult to differentiate RCC from hemorrhagic cysts. Furthermore, CT cannot be used to assess intratumoral blood flow in patients with asthma or iodine hypersensitivity, who cannot receive iodinated contrast media. [6] Magnetic resonance imaging (MRI) can also be performed to assess intratumoral blood flow; however, it has been reported that administration of gadolinium-based contrast agents to patients with renal failure is associated with the development of nephrogenic systemic fibrosis, and currently, use of gadoliniumbased contrast agents is avoided in patients with renal failure. The usefulness of diffusion-weighted MRI, which does not require the use of contrast medium, as a substitute, has also been reported [7] ; however, the cost of MRI is higher than that of US and its accessibility is poor compared with US or CT.
In recent years, there are reports of clinical studies investigating the usefulness of contrast-enhanced ultrasonography in differentiating benign from malignant cystic and solid masses. [8] [9] [10] [11] [12] [13] [14] [15] [16] However, to the best of our knowledge, only 1 case involving imaging of an RCC in a hemodialysis patient using contrastenhanced ultrasonography has been reported [11] ; no clinical systematic studies have investigated the usefulness of contrastenhanced ultrasonography for evaluating renal masses in dialysis patients. Furthermore, the use of perflubutane microbubbles as ultrasonographic contrast agents in the liver has been reported to be associated with high contrast enhancement sensitivity and a low incidence of allergy; in addition, it can be used in patients with asthma or renal function impairment. [17] However, to the best of our knowledge, no detailed study on the use of perflubutane microbubbles as ultrasonographic contrast agents to evaluate renal masses has been performed.
The purpose of this study was to investigate the usefulness of contrast-enhanced ultrasonography with perflubutane for the diagnosis of RCC in dialysis patients.
Material and methods

Patient population
Between December 2012 and March 2017, a total of 1301 dialysis patients underwent abdominal CT at our hospital. Of these dialysis patients, 19 with suspected solid renal tumors were provided an explanation regarding the research and procedures involved in the study; 18 of these patients provided written informed consent and underwent contrast-enhanced ultrasonography beside CT. This prospective study was conducted with the approval of the Ethics Committee.
Suspicion of a solid renal mass was based on the following findings: contrast enhancement ≥10 Hounsfield units (HU) (including equivocal enhancement) on contrast-enhanced CT (in 13 patients with 13 lesions) and trend towards increase in the size of the mass (30.0 ± 12.1% increase [range: 14.8%-46.2%]) during the period prior to involvement in the study (345 ± 103 days; range, 142-421 days) on unenhanced CT (in 5 patients with 6 lesions). Simple cysts with CT values of <20 HU on unenhanced CT, lesions with CT values of ≥20 HU on unenhanced CT but with contrast enhancement of <10 HU on contrast-enhanced CT, which are considered as cysts, and lesions with obvious fat areas diagnosed as angiomyolipoma were not included.
Of the 18 patients, 13 (72%) underwent dynamic contrastenhanced CT and 5 (28%) underwent unenhanced CT. Of the latter 5 patients who underwent unenhanced CT, 3 were able to urinate by themselves and only unenhanced CT was performed to preserve the residual renal function, 1 had a history of adverse reactions to contrast agents, and 1 refused to undergo injection of iodinated contrast medium.
Scanning protocol
The following CT scanners were used: LightSpeed VCT, Discovery CT750 HD, Revolution CT (GE Healthcare, Waukesha, WI), Aquilion 64, and Aquilion ONE (Canon medical systems, Otawara, Japan). In both unenhanced CT and contrastenhanced CT, only renal images were obtained at 120 kVp and 100 to 200 mA with 0.625 to 1 mm collimation. In dynamic contrast-enhanced CT, 50 to 80 mL (body weight Â 0.6 mL/kg) of contrast medium was injected over a period of 25 seconds, and images were obtained at 40 seconds (corticomedullary phase), 90 seconds (nephrographic phase), and 180 seconds (excretory phase) after the contrast injection.
LOGIQ E9 (GE Healthcare) was used for contrast-enhanced ultrasonography. Before imaging, 0.5 mL/body weight of perflubutane microbubbles (Sonazoid, Daiichi-Sankyo Pharmaceuticals, Tokyo, Japan, and GE Healthcare) was administered by intravenous injection, followed by 20 mL of physiological saline. Images were obtained using a convex probe with a center frequency of 4.0 to 6.0 MHz, with focus on the lower border of the mass, and a mechanical index (MI) of 0.16 to 0.24 in the tissue harmonic imaging mode. Images were obtained during a 30-second breath-hold after contrast agent administration.
Data analysis
With regard to CT, contrast-enhanced CT images in the corticomedullary and nephrographic phases and unenhanced CT images with a slice thickness of 1.25 to 2 mm were evaluated. The maximum circular region of interest was set within the solid portion of the mass. CT values were measured in each phase, and the difference between the CT value at the highest contrast enhancement and the unenhanced CT value was defined as contrast enhancement. Images were evaluated by 2 boardcertified radiologists, and the extent of contrast enhancement was determined by consensus: contrast enhancement of ≥20 HU was defined as obvious enhancement, contrast enhancement of 10 to 20 HU was defined as ambiguous enhancement, and contrast enhancement of <10 HU was defined as non-enhancement.
With regard to interpretation of the ultrasonographic images, 2 board-certified radiologists visually evaluated the contrast enhancement of the lesions: contrast enhancement equivalent to or more than that of the renal parenchyma was defined as hyper-enhancement, contrast enhancement lower than that of the renal parenchyma was defined as hypo-enhancement, and barely detectable contrast enhancement was defined as non-enhancement.
The final diagnoses were made based on: There are very few benign tumors that show contrast enhancement of ≥100 HU, [18] [19] [20] and therefore, we considered these lesions as most likely to be RCC. The mean contrast enhancement of these 11 lesions on dynamic contrast-enhanced CT was 82.1 HU (standard deviation [SD], 49.4 HU). The remaining 5 lesions showed no enlargement during follow-up (mean follow-up duration 3.1 years: 1.0-5.2 years), and were diagnosed as cysts, including 1 inflammatory cyst.
Diagnostic performance of contrast-enhanced ultrasonography
Of the 13 lesions assessed by dynamic contrast-enhanced CT, 11 (77%) showed obvious enhancement (mean: 85.5 ± 45.8 HU, range: [25-151 HU]) ( Fig. 1 ). Of these 11 lesions, 10 lesions showed hyper-enhancement on ultrasonography (Fig. 2 ). One lesion that was located at a depth of 9.8 cm from the body surface was difficult to detect by ultrasonography. Of the 10 lesions that showed hyper-enhancement on ultrasonography, 9 were considered to be RCCs, and the remaining 1 lesion was clinically diagnosed as an inflammatory cyst, considering that the lesion decreased in size during the follow-up despite of contrast enhancement by both CT and ultrasonography. Of the 13 lesions assessed by dynamic contrast-enhanced CT, 2 (15%) showed ambiguous enhancement (10 and 15 HU). Of these 2 lesions, 1 showed hyper-enhancement on ultrasonography, and was diagnosed post-surgery as multilocular cystic RCC (Fig. 3) . The other lesion showed no enhancement on contrastenhanced ultrasonography and was diagnosed as a cyst; this lesion did not increase in size during subsequent follow-up (1471 days).
Of the 6 lesions in 5 patients assessed by unenhanced CT, 3 lesions in 2 patients showed hyper-enhancement on contrastenhanced ultrasonography; these lesions were surgically resected, and were histopathologically confirmed as RCCs (double cancer of ACD-associated RCC and clear-cell RCC in 1 patient, and clear-cell RCC in 1 patient). The remaining 3 lesions in 3 patients were diagnosed as cysts by ultrasonography because they showed non-enhancement on contrast-enhanced ultrasonography. In fact, these lesions also did not increase in size during the subsequent follow-up (369, 634, and 1758 days, respectively) and were clinically diagnosed as cysts.
Overall, when the presence or absence of contrast enhancement (≥20 HU) on CT was used as a diagnostic criterion for RCC, 10 (52.6%) of the 19 lesions could be diagnosed by CT, 
Discussion
This study demonstrated that in dialysis patients with suspected solid renal lesions on CT, contrast-enhanced ultrasonography was useful for differentiating between benign and malignant lesions, especially when contrast enhancement was not obvious on CT (2/2 lesions) or contrast-enhanced CT could not be performed (6/6 lesions in 5 patients). The current study also found that almost all lesions showing obvious enhancement on dynamic contrast-enhanced CT, also showed hyper-enhancement on ultrasonography using perflubutane microbubbles (10/11 lesions). These findings are important because when a definitive diagnosis by CT is difficult, contrast-enhanced ultrasonography could be used as an additional or alternative diagnostic tool to CT for evaluating renal masses in dialysis patients without additional radiation exposure.
To the best of our knowledge, this is the first detailed study to use perflubutane microbubbles as ultrasonographic contrast agents to evaluate renal masses. Among the second generation ultrasonographic contrast agents, perflubutane microbubbles reportedly show the strongest enhancement signal of first harmonic in scattered imaging. [21] In addition, perflubutane microbubbles are taken up or trapped by Kupffer cells of the liver in the post-vascular phase; they are also reported to be useful in the evaluation of hepatic masses. [17] In previous studies regarding other second generation ultrasonographic contrast agents, it has been reported that contrast-enhanced ultrasonography with sulfur hexafluoride microbubbles (SonoVue, Bracco, Milan, Italy) is comparable to contrast-enhanced CT in the evaluation of renal solid masses [16] , and that contrast-enhanced ultrasonography with other second-generation contrast agents such as perflutren lipid microsphere (Definity, Lantheus Medical Imaging, North Billerica, United States) and perflutren protein-type A microspheres (Optison, Mallinckrodt St. Louis, United States and GE Healthcare, Waukesha, United States) has high sensitivity (94.7-100%) and specificity (93.9%-95%) for evaluating the indeterminate renal masses on CT or unenhanced ultrasonography. [14, 22, 23] Additionally, Paudice et al reported that, similar to contrast-enhanced CT, contrast-enhanced ultrasonography enabled differentiation of complex cysts from solid lesions in ACDK in renal transplant recipients. [24] Our study adds to the current literature, that is, our findings indicate that contrast-enhanced ultrasonography would also be useful in dialysis patients with suspected renal masses.
Of the 11 lesions that showed obvious enhancement on contrast-enhanced CT, 1 lesion was undetectable by contrastenhanced ultrasonography because it was deep-seated (9.8 cm from the body surface), indicating that contrast-enhanced ultrasonography cannot assess blood flow in some deep-seated lesions. Further, it has been reported that deep-seated lesions located >6 cm from the body surface are difficult to assess quantitatively by contrast-enhanced liver ultrasonography [25] ; this limitation of the contrast-enhanced ultrasonography is expected to be solved in the future by the technological progress of ultrasonographic equipment.
This study had some limitations. First, the number of patients was small, and prospective studies with a large number of patients are required. Second, a definitive pathological diagnosis was not made in all cases, and lesions assessed as benign or malignant based on clinical judgment were also included. However, we believe that the absence of enlargement of the lesion on follow-up of at least 1 year (1228 ± 616 days; range, 369-1909 days) indicated that the lesion was benign.
Conclusion
In dialysis patients with suspected solid renal lesions on CT, contrast-enhanced ultrasonography was useful for differentiating between benign and malignant lesions especially when contrast enhancement was not obvious on CT or contrast-enhanced CT could not be performed. Thus, contrast-enhanced ultrasonography could be used as an additional or alternative diagnostic tool to CT for evaluating renal masses in dialysis patients without additional radiation exposure.
